Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

（编辑 楚丽君） 证券日报网讯 11月19日晚间，阳光诺和发布公告称，北京阳光诺和药物研究股份有限公司（以下简 称"公司"）拟通过发行股份及支付可转换公司债券购买江苏朗研生命科技控股有限公司100%股权，并 向不超过35名特定投资者发行股份募集配套资金（以下简称"本次交易"）。公司于2025年11月18日收到 上海证券交易所（以下简称"上交所"）出具的《关于受理北京阳光诺和药物研究股份有限公司发行股份 购买资产并募集配套资金申请的通知》（上证科审（并购重组）〔2025〕34号）。上交所依据相关规定 对公司报送的发行股份购买资产并募集配套资金的申请文件进行了核对，认为该项申请文件齐备，符合 法定形式，决定予以受理并依法进行审核。 ...

国联民生证券承销保荐有限公司 关于 北京阳光诺和药物研究股份有限公司 发行股份及可转换公司债券购买资产并募集配 套资金暨关联交易 之 独立财务顾问报告 独立财务顾问 二〇二五年十一月 国联民生证券承销保荐有限公司 独立财务顾问报告 声明与承诺 国联民生证券承销保荐有限公司接受北京阳光诺和药物研究股份有限公司 的委托，担任北京阳光诺和药物研究股份有限公司本次发行股份及可转换公司 债券购买资产并募集配套资金暨关联交易事宜的独立财务顾问，就该事项向北 京阳光诺和药物研究股份有限公司全体股东提供独立意见，并制作《国联民生 证券承销保荐有限公司关于北京阳光诺和药物研究股份有限公司发行股份及可 转换公司债券购买资产并募集配套资金暨关联交易之独立财务顾问报告》。 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管 理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》《上市公司监管指引第 9 号——上市公司筹划和实施重大资产重 组的监管要求》和《上海证券交易所上市公司重大资产重组审核规则》等法律 法规 ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 发行股份及可转换公司债券购买资产 并募集配套资金暨关联交易的 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 | 目录 | | --- | | 释义 2 | | --- | | 正文 8 | | 一、 本次交易方案 8 | | 二、 本次交易各方的主体资格 33 | | 三、 本次交易的批准和授权 67 | | 四、 本次交易涉及的重大协议 70 | | 五、 本次交易的标的资产 71 | | 六、 本次交易涉及的债权债务处理及职工安置 152 | | 七、 关联交易及同业竞争 152 | | 八、 本次交易的实质条件 168 | | 九、 本次交易的信息披露 181 | | 十、 本次交易的证券服务机构 182 | | 十一、 相关方买卖股票情况 182 | 释义 本法律意见中提到的下列简称和术语，除非根据上下文另有解释外，其含义 如下： | 阳光诺和、公司、 | 指 | 北京阳光诺和药物研究股份有限公司，系由北京阳光诺 | | --- | --- | --- | | 上市公司 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-101 北京阳光诺和药物研究股份有限公司 关于发行股份及可转换公司债券购买资产并募集配 套资金暨关联交易申请材料获得上海证券交易所受理的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京阳光诺和药物研究股份有限公司（以下简称"公司"）拟通过发行股份 及支付可转换公司债券购买江苏朗研生命科技控股有限公司 100%股权，并向不 超过 35 名特定投资者发行股份募集配套资金（以下简称"本次交易"）。 公司于 2025 年 11 月 18 日收到上海证券交易所（以下简称"上交所"）出 具的《关于受理北京阳光诺和药物研究股份有限公司发行股份购买资产并募集配 套资金申请的通知》（上证科审（并购重组）〔2025〕34 号）。上交所依据相 关规定对公司报送的发行股份购买资产并募集配套资金的申请文件进行了核对， 认为该项申请文件齐备，符合法定形式，决定予以受理并依法进行审核。 公司本次交易尚需经上交所审核，并获得中国证券监督管理委员会（以下简 称"中国证监会"）注册同 ...

股票代码：688621 股票简称：阳光诺和 上市地点：上海证券交易所 北京阳光诺和药物研究股份有限公司 发行股份及可转换公司债券购买资产 并募集配套资金暨关联交易报告书 （申报稿） | 项目 | 交易对方 | | --- | --- | | | 利虔、赣州朗颐投资中心（有限合伙）、刘宇晶、赣州国智股权投资合伙 | | | 企业（有限合伙）、杭州宏腾医药创业投资合伙企业（有限合伙）、杭州 | | | 方汭创业投资合伙企业（有限合伙）、杭州凯泰民德投资合伙企业（有限 | | | 合伙）、丽水同达创业投资合伙企业（有限合伙）、广州广发信德一期健 | | | 康产业投资企业（有限合伙）、杭州海达明德创业投资合伙企业（有限合 | | | 伙）、宁波海达睿盈创业投资合伙企业（有限合伙）、陈春能、广州易简 | | | 鼎虹股权投资合伙企业（有限合伙）、万海涛、苏州中誉赢嘉健康投资合 | | 发行股份 | 伙企业（有限合伙）、广州正达创业投资合伙企业（有限合伙）、康彦 | | 及可转换 | 龙、冯海霞、武汉火炬创业投资有限公司、武汉开发投资有限公司、珠海 | | 公司债券 | | | | 横琴中润康健投资合伙企业（有限合伙） ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-102 北京阳光诺和药物研究股份有限公司 关于发行股份及可转换公司债券购买资产并募集配 套资金暨关联交易报告书（申报稿） | 重组报告书主要章节 | 重组报告书修订情况说明 | | --- | --- | | 第八节 本次交易的合规 | 更新"八、本次交易符合《收购管理办法》第七十四条、第六十 一条第一款第（一）项、第六十三条第一款第（三）项的规定" | | 性分析 | | | | 关于审议情况的表述。 | | 第十二节 风险因素 | 更新"一、（一）本次交易的审批、核准风险"。 | | 第十四节 独立董事及中 | | | 介机构关于本次交易出 | 更新"三、法律顾问意见"的结论性意见。 | | 具的意见 | | | 附件 | 1、更新"附件一：交易对方历史沿革概况"中朗颐投资、广州 | | | 正达的历史沿革； | | | 2、补充更新"附件二、交易对方穿透核查情况"。 | 特此公告。 北京阳光诺和药物研究股份有限公司董事会 2025 年 11 月 20 日 公司于 2025 年 11 月 18 日收到上海证券交易所出具的《关于受理北京阳光 诺 ...

阳光诺和公告，公司拟通过发行股份及支付可转换公司债券购买江苏朗研生命科技控股有限公司100% 股权，并向不超过35名特定投资者发行股份募集配套资金。公司于2025年11月18日收到上海证券交易所 出具的《关于受理北京阳光诺和药物研究股份有限公司发行股份购买资产并募集配套资金申请的通 知》。上交所决定予以受理并依法进行审核。本次交易尚需经上交所审核，并获得中国证监会注册同意 后方可实施。 ...

Core Viewpoint - Yangguang Nuohuo (688621) has received approval from the Shanghai Stock Exchange for its application to issue shares for asset acquisition, indicating a strategic move to enhance its asset base and financial position [1] Group 1: Financing Details - The company plans to raise a total of 865 million yuan through this issuance, which reflects its commitment to securing necessary funds for the acquisition [1] - The independent financial advisor for this issuance is Guolian Minsheng Securities Co., Ltd., highlighting the involvement of established financial institutions in the process [1]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, and others [1]. Core Views - The pharmaceutical sector experienced a 3.29% increase this week, outperforming the CSI 300 index by 4.37 percentage points. Sub-sectors such as pharmaceutical commerce, pharmacies, and innovative drugs performed well, while medical devices and consumables lagged [2][12]. - The report emphasizes the importance of market pricing power and the impact of liquidity and risk appetite on investment strategies, particularly in innovative drugs and related supply chains [2][12]. - The report highlights the upcoming patent expirations for small molecule drugs, which are expected to create significant demand for raw materials, with a projected sales impact of $390 billion from 2025 to 2030 [3][13]. Summary by Sections Industry Performance - The pharmaceutical sector's performance this week was characterized by a 3.29% increase, with notable performances in pharmaceutical commerce (+7.31%), pharmacies (+6.83%), and innovative drugs (+5.01%). In contrast, medical devices (0.16%) and new medical infrastructure (1.18%) showed weaker performance [17][29]. - The overall price-to-earnings (P/E) ratio for the pharmaceutical industry is reported at 30.84 times, with a premium of 25.08% compared to the overall A-share market excluding the financial sector [33]. Company Dynamics - Notable company announcements include: - Prologis Pharmaceuticals received a European certificate for its product, enhancing its international market prospects [18]. - Jianyou Co. announced FDA approval for its production site, expanding its manufacturing capabilities [19]. - Fuyuan Pharmaceuticals received a drug registration certificate from the National Medical Products Administration, allowing for the marketing of its product [20]. - The report suggests focusing on companies benefiting from domestic innovative drug support policies, such as Yangguang Nuohuo and Nuosige, as well as those with strong overseas business prospects [15][7]. Raw Materials - The report indicates that the raw materials sector is expected to see a significant increase in demand due to patent expirations, with a projected sales impact of $390 billion from 2025 to 2030. The production of raw materials in H1 2025 reached 1.935 million tons, reflecting an 8.2% year-on-year increase [3][13]. - Companies recommended for attention in the raw materials sector include Aorite, Prologis Pharmaceuticals, and Aoxiang Pharmaceuticals, focusing on innovation and strong performance [3][16].